Secondary acute myeloid leukemia after successful treatment for osteosarcoma | Zendy

Rakesh Mittal | Zendy; Noorni V. Ramaswamy | Zendy; Ramesh Pandita | Zendy; Soad Al Bahar | Zendy; Nisreen Khalifa | Zendy; Souheil Omar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Secondary acute myeloid leukemia after successful treatment for osteosarcoma

Author(s) -

Rakesh Mittal,

Noorni V. Ramaswamy,

Ramesh Pandita,

Soad Al Bahar,

Nisreen Khalifa,

Souheil Omar

Publication year - 2010

Publication title -

indian journal of medical and paediatric oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.229

H-Index - 22

eISSN - 0975-2129

pISSN - 0971-5851

DOI - 10.4103/0971-5851.68852

Subject(s) - medicine , leukocytosis , myeloid leukemia , osteosarcoma , cisplatin , chemotherapy , complication , amputation , leukemia , induction chemotherapy , surgery , myeloid sarcoma , sarcoma , oncology , cancer research , pathology

Secondary acute myeloid leukemia (sAML) is a rare complication following chemotherapy for osteogenic sarcoma. However, the exact offending drug is difficult to prove as there is no consistent data. It usually develops 2 years after completion of therapy. We report a case of sAML that developed within 8 months of completing the treatment. The patient was treated with cisplatin, doxorubicin and high-dose methotreaxate followed by surgery (amputation). Eight months after completion of therapy, while on follow-up, he presented with leukocytosis and thrombocytopenia and confirmed to have AML.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research